Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e137-

  Suzuki, Kazuo ^a   Hattori, Shinichiro ^b   Marks, Katherine ^a   Ahlenstiel, Chantelle ^c   Maeda, Yosuke ^b   Ishida, Takaomi ^d   Millington, Michelle ^e   Boyd, Maureen ^e   Symonds, Geoff ^a,e   Cooper, David A ^a,c   Okada, Seiji ^b   Kelleher, Anthony D ^a,c  

^a St Vincent s Centre for Applied Medical Research   (Australia)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d THE UNIVERSITY OF TOKYO   (Japan)

^e Calimmune Australia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; LENTIVIRUS VECTOR; PROMA PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EX VIVO STUDY; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; SERUM; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 85015372182     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.64     Document Type: Article

References (64)

1. 1 Ho, DD, Neumann, AU, Perelson, AS, Chen, W, Leonard, JM, Markowitz, M, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995), 123–126.
2. 2 Mellors, JW, Rinaldo, CR, Gupta, P, White, RM, Todd, JA, Kingsley, LA, Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996), 1167–1170.
3. 3 Perelson, AS, Essunger, P, Cao, Y, Vesanen, M, Hurley, A, Saksela, K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997), 188–191.
4. 4 Palella, FJ, Delaney, KM, Moorman, AC, Loveless, MO, Fuhrer, J, Satten, GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998), 853–860.
5. 5 Chun, TW, Finzi, D, Margolick, J, Chadwick, K, Schwartz, D, Siliciano, RF, In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1 (1995), 1284–1290.
6. 6 Finzi, D, Hermankova, M, Pierson, T, Carruth, LM, Buck, C, Chaisson, RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997), 1295–1300.
7. 7 Siliciano, RF, Greene, WC, HIV latency. Cold Spring Harb Perspect Med, 1, 2011, a007096.
8. 8 Wong, JK, Hezareh, M, Günthard, HF, Havlir, DV, Ignacio, CC, Spina, CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 (1997), 1291–1295.
9. 9 Chun, TW, Justement, JS, Moir, S, Hallahan, CW, Maenza, J, Mullins, JI, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195 (2007), 1762–1764.
10. 10 Turner, AM, De La Cruz, J, Morris, KV, Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression. Mol Ther 17 (2009), 360–368.
11. 11 Malecová, B, Morris, KV, Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. Curr Opin Mol Ther 12 (2010), 214–222.
12. 12 Suzuki, K, Kelleher, AD, Transcriptional regulation by promoter targeted RNAs. Curr Top Med Chem 9 (2009), 1079–1087.
13. 13 Suzuki, K, Kelleher, AD, Lessons from viral latency in T cells: manipulating HIV-1 transcription by siRNA. HIV Therapy 4 (2010), 199–213.
14. 14 Ahlenstiel, CL, Lim, HG, Cooper, DA, Ishida, T, Kelleher, AD, Suzuki, K, Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. Nucleic Acids Res 40 (2012), 1579–1595.
15. 15 Knowling, S, Stapleton, K, Turner, AM, Uhlmann, E, Lehmann, T, Vollmer, J, et al. Chemically Modified Oligonucleotides Modulate an Epigenetically Varied and Transient Form of Transcription Silencing of HIV-1 in Human cells. Mol Ther Nucleic Acids, 1, 2012, e16.
16. 16 Turner, AM, Ackley, AM, Matrone, MA, Morris, KV, Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells. Hum Gene Ther 23 (2012), 473–483.
17. 17 Turunen, MP, Lehtola, T, Heinonen, SE, Assefa, GS, Korpisalo, P, Girnary, R, et al. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ Res 105 (2009), 604–609.
18. 18 Novina, CD, Murray, MF, Dykxhoorn, DM, Beresford, PJ, Riess, J, Lee, SK, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 8 (2002), 681–686.
19. 19 Jacque, JM, Triques, K, Stevenson, M, Modulation of HIV-1 replication by RNA interference. Nature 418 (2002), 435–438.
20. 20 Boden, D, Pusch, O, Lee, F, Tucker, L, Ramratnam, B, Human immunodeficiency virus type 1 escape from RNA interference. J Virol 77 (2003), 11531–11535.
21. 21 Das, AT, Brummelkamp, TR, Westerhout, EM, Vink, M, Madiredjo, M, Bernards, R, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 78 (2004), 2601–2605.
22. 22 von Eije, KJ, ter Brake, O, Berkhout, B, Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol 82 (2008), 2895–2903.
23. 23 Westerhout, EM, Ooms, M, Vink, M, Das, AT, Berkhout, B, HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 33 (2005), 796–804.
24. 24 Shah, PS, Pham, NP, Schaffer, DV, HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther 20 (2012), 840–848.
25. 25 ter Brake, O, Konstantinova, P, Ceylan, M, Berkhout, B, Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 14 (2006), 883–892.
26. 26 Wassenegger, M, Heimes, S, Riedel, L, Sänger, HL, RNA-directed de novo methylation of genomic sequences in plants. Cell 76 (1994), 567–576.
27. 27 Wassenegger, M, RNA-directed DNA methylation. Plant Mol Biol 43 (2000), 203–220.
28. 28 Mette, MF, Matzke, AJ, Matzke, MA, Resistance of RNA-mediated TGS to HC-Pro, a viral suppressor of PTGS, suggests alternative pathways for dsRNA processing. Curr Biol 11 (2001), 1119–1123.
29. 29 Jones, L, Ratcliff, F, Baulcombe, DC, RNA-directed transcriptional gene silencing in plants can be inherited independently of the RNA trigger and requires Met1 for maintenance. Curr Biol 11 (2001), 747–757.
30. 30 Sibley, CR, Seow, Y, Wood, MJ, Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 18 (2010), 466–476.
31. 31 Roberts, TC, Andaloussi, SE, Morris, KV, McClorey, G, Wood, MJ, Small RNA-Mediated Epigenetic Myostatin Silencing. Mol Ther Nucleic Acids, 1, 2012, e23.
32. 32 Miller, V, Larder, BA, Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther (Lond) 6 (2001), 25–44 suppl. 3.
33. 33 Klenerman, P, Wu, Y, Phillips, R, HIV: current opinion in escapology. Curr Opin Microbiol 5 (2002), 408–413.
34. 34 Suzuki, K, Juelich, T, Lim, H, Ishida, T, Watanebe, T, Cooper, DA, et al. Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region. J Biol Chem 283 (2008), 23353–23363.
35. 35 Weinberg, MS, Barichievy, S, Schaffer, L, Han, J, Morris, KV, An RNA targeted to the HIV-1 LTR promoter modulates indiscriminate off-target gene activation. Nucleic Acids Res 35 (2007), 7303–7312.
36. 36 Jackson, AL, Bartz, SR, Schelter, J, Kobayashi, SV, Burchard, J, Mao, M, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21 (2003), 635–637.
37. 37 Hornung, V, Guenthner-Biller, M, Bourquin, C, Ablasser, A, Schlee, M, Uematsu, S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11 (2005), 263–270.
38. 38 Judge, AD, Sood, V, Shaw, JR, Fang, D, McClintock, K, MacLachlan, I, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23 (2005), 457–462.
39. 39 Suzuki, K, Shijuuku, T, Fukamachi, T, Zaunders, J, Guillemin, G, Cooper, D, et al. Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing 1 (2005), 66–78.
40. 40 Lim, HG, Suzuki, K, Cooper, DA, Kelleher, AD, Promoter-targeted siRNAs induce gene silencing of simian immunodeficiency virus (SIV) infection in vitro. Mol Ther 16 (2008), 565–570.
41. 41 Yamagishi, M, Ishida, T, Miyake, A, Cooper, DA, Kelleher, AD, Suzuki, K, et al. Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes Infect 11 (2009), 500–508.
42. 42 Suzuki, K, Ishida, T, Yamagishi, M, Ahlenstiel, C, Swaminathan, S, Marks, K, et al. Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biol 8 (2011), 1035–1046.
43. 43 Hattori, S, Ide, K, Nakata, H, Harada, H, Suzu, S, Ashida, N, et al. Potent activity of a nucleoside reverse transcriptase inhibitor, 4’-ethynyl-2-fluoro-2’-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother 53 (2009), 3887–3893.
44. 44 Weinberg, MS, Villeneuve, LM, Ehsani, A, Amarzguioui, M, Aagaard, L, Chen, ZX, et al. The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA 12 (2006), 256–262.
45. 45 Brummelkamp, TR, Bernards, R, Agami, R, A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002), 550–553.
46. 46 Colin, L, Van Lint, C, Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology, 6, 2009, 111.
47. 47 Folks, TM, Justement, J, Kinter, A, Dinarello, CA, Fauci, AS, Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238 (1987), 800–802.
48. 48 Della Chiara, G, Crotti, A, Liboi, E, Giacca, M, Poli, G, Lusic, M, Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex. J Mol Biol 410 (2011), 933–943.
49. 49 Matalon, S, Rasmussen, TA, Dinarello, CA, Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 17 (2011), 466–472.
50. 50 Zhou, J, Neff, CP, Liu, X, Zhang, J, Li, H, Smith, DD, et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther 19 (2011), 2228–2238.
51. 51 Neff, CP, Zhou, J, Remling, L, Kuruvilla, J, Zhang, J, Li, H, et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med, 3, 2011, 66ra6.
52. 52 ter Brake, O, Legrand, N, von Eije, KJ, Centlivre, M, Spits, H, Weijer, K, et al. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model. Gene Ther 16 (2009), 148–153.
53. 53 Shimizu, S, Hong, P, Arumugam, B, Pokomo, L, Boyer, J, Koizumi, N, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115 (2010), 1534–1544.
54. 54 Centlivre, M, Legrand, N, Klamer, S, Liu, YP, Eije, KJ, Bohne, M, et al. Preclinical In Vivo Evaluation of the Safety of a Multi-shRNA-based Gene Therapy Against HIV-1. Mol Ther Nucleic Acids, 2, 2013, e120.
55. 55 Freed, EO, Martin, MA, HIVs and their replication. Fields Virology, 2001, Lippincott Williams & Wilkins, New York.
56. 56 Jeang, KT, Xiao, H, Rich, EA, Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 274 (1999), 28837–28840.
57. 57 Greene, WC, Peterlin, BM, Charting HIV's remarkable voyage through the cell: basic science as a passport to future therapy. Nat Med 8 (2002), 673–680.
58. 58 Kalebic, T, Kinter, A, Poli, G, Anderson, ME, Meister, A, Fauci, AS, Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci USA 88 (1991), 986–990.
59. 59 Okada, S, Harada, H, Ito, T, Saito, T, Suzu, S, Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice intrahepatic engrafted with cord blood-derived CD34 + cells. Int J Hematol 88 (2008), 476–482.
60. 60 Fernandez, G, Zeichner, SL, Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J, 7, 2010, 266.
61. 61 Wightman, F, Ellenberg, P, Churchill, M, Lewin, SR, HDAC inhibitors in HIV. Immunol Cell Biol 90 (2012), 47–54.
62. 62 Miyoshi, H, Takahashi, M, Gage, FH, Verma, IM, Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 94 (1997), 10319–10323.
63. 63 Zhang, B, Xia, HQ, Cleghorn, G, Gobe, G, West, M, Wei, MQ, A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene Ther 8 (2001), 1745–1751.
64. 64 Suzuki, K, Craddock, BP, Okamoto, N, Kano, T, Steigbigel, RT, Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase. J Virol Methods 44 (1993), 189–198.